For the first time in more than a century of insulin therapy, children with type 1 diabetes have a mealtime insulin option that requires no needle.
The FDA approved Afrezza (insulin human inhalation powder; MannKind Corporation) for use in children and adolescents ages 6 and older with type 1 or type 2 diabetes on May 29, 2026 — expanding the drug's indication from adults to the pediatric population for the first time since Afrezza was originally approved in 2014.
